Condensed Consolidated Statements of Operations - (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue	$ 2,000	$ 987
Operating expenses:
Research and development	3,133	3,103
General and administrative	5,348	2,164
Total operating expenses	8,481	5,267
Operating loss	(6,481)	(4,280)
Other expense	(3,234)
Other income (expense) – related party	492	(1,648)
Interest income		1
Interest expense	(1)
Loss before income taxes and noncontrolling interest	(9,224)	(5,927)
Income tax provision	200	15
Net loss before noncontrolling interest	(9,424)	(5,942)
Less: net loss attributable to noncontrolling interest	(2,417)	(1,701)
Net loss attributable to vTv Therapeutics Inc.	(7,007)	(4,241)
Net loss attributable to vTv Therapeutics Inc. common shareholders	$ (7,007)	$ (4,241)
Class A Common Stock [Member]
Operating expenses:
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	$ (0.10)	$ (0.08)
Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	66,942,777	56,472,535